Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA Pembrolizumab PET Imaging in NSCLC Patients Receiving SBRT
NCT07619599Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-DOTA-pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Primary endpoints: Incidence of treatment-related adverse events and Maximum standard uptake value at Day 44. Started Sep 2026; status: recruiting.
02
Drugs
64Cu-DOTA-pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07619599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619599.